Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab


  • Stephen R. Grobmyer
  • Nobutaka Iwakuma
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3967-2


Is the rapidly progressing interdisciplinary field that is focused on the engineering and development of man-made structures between 1 and 100 nm? One nanometer equals 1 × 10−9 m. Cancer nanotechnology is focused specifically on the application of nanotechnology to the diagnosis and treatment of cancer.


Nanotechnology involves the engineering of man-made structures ranging between 1 and 100 nm (Fig. 1). Nanotechnology is an interdisciplinary field that includes chemical engineering, physics, chemistry, biomedical engineering, and material and particle science. Cancer nanotechnology specifically also incorporates the expertise of cancer biologists and oncologists. The goal of cancer nanotechnology is to utilize nanotechnology to improve early diagnosis and treatment of cancer. Nanotechnology has the potential to capitalize on advances in cancer biology, genomics, and proteomics and convert advances into clinical benefit for patients.


Contrast Agent Gold Nanoparticles Sentinel Lymph Node Biopsy Magnetic Resonance Imaging Contrast Agent Nanoscale Particle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Cuenca AG, Jiang H, Hochwald SN et al (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer 107(3):459–466CrossRefPubMedGoogle Scholar
  2. Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171CrossRefPubMedGoogle Scholar
  3. Moghimi SM, Hunter AC, Murray JC (2005) Nanomedicine: current status and future prospects. FASEB J 19(3):311–330CrossRefPubMedGoogle Scholar
  4. Portney NG, Ozkan M (2006) Nano-oncology: drug delivery, imaging, and sensing. Anal Bioanal Chem 384(3):620–630CrossRefPubMedGoogle Scholar
  5. Sinha R, Kim GJ, Nie S et al (2006) Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 5(8):1909–1917CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Surgery, Division of Surgical OncologyUniversity of FloridaGainesvilleUSA